Immunogenx, Inc.

Newport Beach, CA

UEI
DHJSMHJ9BJE5
CAGE
6Y1F1
Primary NAICS
325414 Biological Product (except Diagnostic) Manufacturing
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • For Profit Organization
  • Woman Owned Small Business
  • Woman Owned Business
Entity structure
Corporate Entity (Not Tax Exempt)
Other NAICS codes in SAM.gov
SAM.gov registration date
Physical address
1600 Dove St #330, Newport Beach, CA 92660, USA
Website
immunogenx.com
Founded
2013
Employees
1-10
Estimated annual revenue
$0-$1M
Industry
  1. Health Care
  2. Pharmaceuticals, Biotechnology & Life Sciences
  3. Pharmaceuticals
SIC code
28 Chemical & Allied Products
Profiles

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Grant awards

Award Agency Obligated Awarded
A clinical study of latiglutenase as a treatment for type 1 diabetics with celiac disease R44DK121606 National Institute of Diabetes and Digestive and Kidney Diseases (NIH) $4,071,577
A clinical study of latiglutenase as a treatment for symptom reduction for celiac disease U44AI134590 National Institute of Allergy and Infectious Diseases (NIH) $5,789,282
Latiglutenase as a treatment for celiac disease R33AT009637 National Center for Complementary and Integrative Health (NIH) $874,356

Quick answers

Is Immunogenx, Inc. registered in SAM.gov?

Yes. Immunogenx, Inc.'s SAM.gov registration is active through September 27, 2027.

What is Immunogenx, Inc.'s most recent federal award?

Immunogenx, Inc.'s most recent federal grant award is A clinical study of latiglutenase as a treatment for type 1 diabetics with celiac disease (R44DK121606), from National Institute of Diabetes and Digestive and Kidney Diseases (NIH), on September 8, 2020.

On GovTribe

See Immunogenx, Inc.'s full federal record

  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login